Neurocrine Biosciences
$14.31 B
Share price
Change (1 day)
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) Fails to deliver data

Key failure to deliver metrics for Neurocrine Biosciences :

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Neurocrine Biosciences (NBIX) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Neurocrine Biosciences (NBIX) - since 2013

Volume in USD (price x number of shares), data since 2013

Neurocrine Biosciences (NBIX) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024$15.7 M-28.34%
2023$21.91 M-32.24%
2022$32.34 M-26.75%
2021$44.16 M193.08%
2020$15.06 M-65.24%
2019$43.34 M-3.16%
2018$44.76 M-18.56%
2017$54.96 M78.43%
2016$30.8 M53.41%
2015$20.07 M66.9%
2014$12.03 M241.08%
2013$3.52 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
$10.32 M$0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
$8.72 M$79.91 M๐Ÿ‡บ๐Ÿ‡ธ USA
$56.64 M$0.12 B๐Ÿ‡บ๐Ÿ‡ธ USA
$11.94 M$0.10 B๐Ÿ‡บ๐Ÿ‡ธ USA
$0.09 M$0.71 M๐Ÿ‡บ๐Ÿ‡ธ USA
$0.12 M$1.19 M๐Ÿ‡บ๐Ÿ‡ธ USA
$1.52 M$1.81 M๐Ÿ‡บ๐Ÿ‡ธ USA
$0.59 M$18.4 M๐Ÿ‡ฌ๐Ÿ‡ง UK